Intimate partner violence (IPV) is defined as threatened, attempted, or completed physical or sexual violence or emotional abuse by a current or former intimate partner. IPV can be committed by a spouse, an ex-spouse, a current or former boyfriend or girlfriend, or a dating partner (1). Each year, IPV results in an estimated 1,200 deaths and 2 million injuries among women and nearly 600,000 injuries among men (1). In addition to the risk for death and injury, IPV has been associated with certain adverse health conditions and health risk behaviors (1). To gather additional information regarding the prevalence of IPV and to assess the association between IPV and selected adverse health conditions and health risk behaviors, CDC included IPV-related questions in an optional module of the 2005 Behavioral Risk Factor Surveillance System (BRFSS) survey. This report describes the results of that survey, which indicated that persons who report having experienced IPV during their lifetimes also are more likely to report current adverse health conditions and health risk behaviors. Although a causal link between IPV and adverse health conditions cannot be inferred from these results, they underscore the need for IPV assessment in health-care settings. In addition, the results indicate a need for secondary intervention strategies to address the health-related needs of IPV victims and reduce their risk for subsequent adverse health conditions and health risk behaviors.
Intimate partner violence (IPV) is defined as threatened, attempted, or completed physical or sexual violence or emotional abuse by a current or former intimate partner. IPV can be committed by a spouse, an ex-spouse, a current or former boyfriend or girlfriend, or a dating partner (1) . Each year, IPV results in an estimated 1,200 deaths and 2 million injuries among women and nearly 600,000 injuries among men (1) . In addition to the risk for death and injury, IPV has been associated with certain adverse health conditions and health risk behaviors (1) . To gather additional information regarding the prevalence of IPV and to assess the association between IPV and selected adverse health conditions and health risk behaviors, CDC included IPV-related questions in an optional module of the 2005 Behavioral Risk Factor Surveillance System (BRFSS) survey. This report describes the results of that survey, which indicated that persons who report having experienced IPV during their lifetimes also are more likely to report current adverse health conditions and health risk behaviors. Although a causal link between IPV and adverse health conditions cannot be inferred from these results, they underscore the need for IPV assessment in health-care settings. In addition, the results indicate a need for secondary intervention strategies to address the health-related needs of IPV victims and reduce their risk for subsequent adverse health conditions and health risk behaviors.
BRFSS is an annual, state-based, random-digit-dialed telephone survey of the noninstitutionalized, U.S. civilian population aged >18 years. The survey solicits information on a range of health conditions and health risk behaviors. Data are weighted to account for probability of selection and to match the age-, race/ethnicity-, and sex-specific populations from annually adjusted intercensal estimates. In 2005, a total of 70,156 respondents (42,566 women and 27,590 men) in 16 states and two territories* completed the optional IPV module. Among these 18 states/ territories, the median response rate for the 2005 BRFSS core survey, based on Council of American Survey and Research Organizations (CASRO) guidelines, was 51.6% (range: 37.8% [Massachusetts] to 72.7% [Puerto Rico]). The design and characteristics of BRFSS have been described previously. † Logistic regression models were stratified by sex and included age, race/ethnicity, annual household income, and education level as control variables. Statistical significance (p<0.05) was determined using the Wald chi-square test.
The IPV module included four questions regarding physical or sexual violence by a current or former intimate partner that respondents had experienced during their lifetimes. Respondents were classified as having experienced IPV if they reported that any of the following had occurred during their lifetimes: threatened, attempted, or completed physical violence or unwanted sex by a current or former intimate partner. § Health conditions and risk behaviors were selected to cover the full range of conditions and behaviors assessed by BRFSS. These included two self-reported health conditions: 1) current use of disability equipment (e.g., a cane, wheelchair, or special bed) and 2) current activity limitations because of physical, mental, or emotional problems. Respondents also were asked whether they had ever been told by a doctor, nurse, or other health-care professional that they had 1) high blood cholesterol; 2) nongestational high blood pressure; 3) nongestational diabetes; 4) cardiovascular disease (e.g., heart attack, angina, coronary heart disease, or stroke); 5) joint disease (e.g., arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia); or 6) current asthma. In addition, selected health risk behaviors were assessed: 1) risk factors for human immunodeficiency virus (HIV) infection or sexually transmitted diseases (STDs) (i.e., if, during the preceding year, respondent had used intravenous drugs, had been treated for an STD, had given or received money or drugs in exchange for sex, or had participated in anal sex without a condom); 2) current smoking; 3) heavy or binge alcohol use (i.e., more than two drinks per day on average for men, more than one drink per day on average for women, or five or more drinks on one occasion during the preceding 30 days for men and women); and 3) having a body mass index (BMI) (weight [kg] / height [m 2 ]) >25. ¶ Lifetime IPV prevalence estimates were calculated by sex, age group, race/ethnicity, annual household income, and education level (Table 1) . Lifetime IPV prevalence was significantly higher (p<0.05) among women than among men; higher among multiracial, non-Hispanic, and American Indian/Alaska Native women; and higher among lowerincome respondents. Because BRFSS is a cross-sectional survey, these findings cannot address causality. For example, whether adverse health outcomes are caused by IPV cannot be inferred. Evidence from other studies, however, suggests that one underlying mechanism that might link IPV and chronic diseases is the biologic response to long-term or ongoing stress (2) (3) (4) (5) . For example, the link between violence, stress, and somatic disorders (e.g., fibromyalgia, chronic fatigue syndrome, temporomandibular disorder, and irritable bowel syndrome) has been well established (3, 5) . These same stress responses also have been linked to various chronic diseases, including cardiovascular disease, asthma, diabetes, and gastrointestinal disorders (3, 6) . Conversely, adverse health conditions might, in certain cases, lead to increased IPV. Data suggest that women with disabilities experience more IPV than those without disabilities (7) .
The findings in this report are subject to at least three other limitations. First, because BRFSS is a telephone survey of residential households, persons without landline telephones (i.e., those with no telephone or with a cellular telephone only) are not represented in the sample. Second, because not all states/territories administered the IPV module, the data might not be representative of the entire U.S. adult population. Finally, although these findings indicated an association between IPV and adverse health conditions and health risk behaviors, not all persons who experience IPV would be expected to experience these conditions and behaviors. The number and range of questions that could be included in the IPV module were limited, and information was not collected on the severity, frequency, and context of IPV experienced by respondents. These important factors likely would influence the observed association between IPV and adverse health conditions and health risk behaviors.
Whether IPV is followed by adverse health conditions or adverse health conditions lead to IPV, both are likely to affect the overall health of affected persons, suggesting that clinicians should consider assessing exposure to IPV when patients have signs or symptoms of stress or other conditions that are consistent with IPV. Such assessment might influence the diagnosis, treatment plan, and ability of the patient to adhere to treatment. Assessing exposure to IPV (10) . This compilation includes an inventory of tools that can be used by health-care providers to determine whether a patient is a victim of IPV or sexual violence and to identify those patients requiring additional services or referrals.
State Medicaid Coverage for Tobacco-Dependence Treatments -United States, 2006
Approximately one third of adult Medicaid recipients smoke (1) . The Public Health Service (2), the Task Force on Community Preventive Services (3), and the Institute of Medicine (4) recommend that health-insurance coverage be provided for tobacco-dependence treatments. In addition, a Healthy People 2010 national health objective calls for total health-insurance coverage for evidence-based tobacco-dependence treatments in all 51 Medicaid programs (objective 27-8b) (5 In October 2006, state Medicaid program directors were asked to identify staff members who were most knowledgeable about coverage and programs for tobacco-dependence treatment, and a survey was e-mailed to the identified staff member in each state. Follow-up was conducted through telephone, e-mail, and fax; the response rate was 100%. The survey included questions regarding coverage of tobacco-dependence treatments, the year coverage was first offered, treatments offered to pregnant women, and program requirements for patient copayments or limitations on use of treatments. The 2006 survey, for the first time, included a question regarding coverage for the nicotine lozenge and varenicline (Chantix). Medicaid programs also were asked to submit either a written copy of their coverage policies for tobacco-dependence treatments or a copy of related documentation. Of the 43 programs that reported offering coverage in 2006, a total of 41 provided some supporting documentation: 23 provided detailed documentation matching their survey responses (although seven were missing documentation regarding Chantix), 17 provided partial benefit information (e.g., documentation for pharmacotherapy but not counseling), and one provided general benefit information (i.e., mentioned coverage but did not specify which treatments were covered).
A total of 39 (76.5%) Medicaid programs reported offering coverage for at least one form of tobaccodependence treatment for their entire Medicaid population (Table 1 ). In addition, four states reported offering coverage for pregnant women only. Of the 39 programs that offered any coverage to their entire Medicaid population, all covered some pharmacotherapy: Zyban ® (GlaxoSmithKline, Research Triangle Park, North Carolina) or its generic equivalent (bupropion) (37 programs), nicotine patches (36), nicotine gum (34), varenicline (Chantix) (32), nicotine nasal spray (30), nicotine inhalers (30), and nicotine lozenges (28).
Seventeen states covered some form of tobacco-cessation counseling services for their entire Medicaid population ( In three states (California, New York, and Rhode Island), tobacco-dependence treatments were covered for enrollees in Medicaid managed-care organizations but not for those in fee-for-service Medicaid programs. For example, in Rhode Island, a legislative mandate for coverage of tobaccodependence treatment in managed-care organizations resulted in coverage for all forms of nicotine-replacement therapy for enrollees in Medicaid managed-care organizations, whereas fee-for-service enrollees were covered for counseling services only.* Many Medicaid programs had limitations on coverage of tobacco-dependence treatment, including copayments, requirements for prior authorization to obtain coverage, limitations on treatment duration, requirements that patients try one form of therapy before beginning another (i.e., stepped-care therapy), and provision of coverage for one type of tobacco-dependence treatment at a time. Requiring copayments for tobacco-dependence treatments was the most common limitation among Medicaid programs. Among the 43 programs that covered any tobaccodependence treatments (either for all recipients or for pregnant women), 72% required copayments (Table 2); 14 required copayments for all covered tobacco-dependence treatments (medications and counseling), and 17 required copayments for specific tobacco-dependence treatments, including 11 states that required copayments for all types of pharmacotherapy but none for counseling, three states that required copayments for brand-name tobaccodependence drugs but not for generic drugs, and three states that required copayments for certain, but not all, medications. Among the 40 programs covering any generic drugs † † P = Medicaid coverage exclusively for pregnant women. § § Response differs from previous year's survey because of a previous reporting error. In most cases, this resulted from the state reporting on managed-care organization voluntary coverage of tobacco-dependence treatments and not Medicaid coverage policies. ¶ ¶ Fee-for-service Medicaid did not cover, but Medicaid managed-care organizations were required to cover. *** Covered only after the gum or patch was used in conjunction with quitline support for 2 weeks.
† † † State did not have any documentation or knowledge regarding the year coverage began. § § § Counseling indicated was not specific to tobacco-cessation counseling. * Patients required to try one form of therapy before beginning another. † Required for certain covered tobacco-dependence treatments but not others. § Required for pharmacotherapy but not counseling. ¶ Required for brand-name drugs but not generic. ** Required for coverage exceeding 90 days. † † Pharmacotherapy in Rhode Island was covered by managed-care organizations only. § § Arizona, Iowa, and Kentucky offered coverage for counseling only (i.e., not for pharmacotherapy); only the copayment question applies to these three states.
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for tobacco-dependence treatment, 26 (65%) required copayments for generic drugs (median: $2 per prescription; range: $1-$5). Of the 40 programs covering any brandname drugs for tobacco-dependence treatment, 30 (75%) required copayments (median: $3; range: $1-$15). Of the 27 programs covering counseling, five (19%) required copayments (median: $2; range: $1-$3) for these services.
Prior authorization for tobacco-dependence treatments was required by 20 states, with six states requiring prior authorization for all pharmacologic tobacco-dependence treatments and 14 states requiring prior authorization for selected treatments (Table 2 ). Twenty-two Medicaid programs had limitations on the duration of treatment for medications (median: 12 weeks). Twenty-one had limitations on the number of courses of pharmacologic treatment per year (median: one course); four programs (Colorado, Louisiana, Montana, and North Dakota) applied these limits to a lifetime benefit. Seven state Medicaid programs used stepped-care therapy, which requires use of a specific tobacco-dependence treatment before any other treatments are covered. Eleven states required enrollees to participate in counseling services to be eligible for pharmacotherapy coverage, even though two of these programs did not cover counseling. Nine states reported that Medicaid paid for one tobacco-dependence medication at a time. Editorial Note: Ten percent of U.S. smokers have a tobaccorelated disease (7) . Each year, tobacco use in the United States results in $193 billion in health-care costs and lost productivity (8) , including an estimated 14% of Medicaid costs (9) . Approximately 35% of adult Medicaid recipients were current smokers in 2006 (1). Effective tobaccodependence treatments include FDA-approved pharmacotherapy and individual, group, and telephone counseling (2) . Evidence indicates that tobacco-dependence treatment is highly cost-effective, even cost-saving, in certain populations (10) . Nonetheless, certain states might be reluctant to add a new Medicaid benefit when facing state Medicaid budget cuts. In 2006, eight states provided no Medicaid coverage for tobacco-dependence treatments, only seven states covered all FDA-approved medications and at least one form of counseling for all enrollees, and only one state (Oregon) covered all treatments recommended by the Clinical Practice Guideline (2) .
In 2006, measures that limited use of tobaccodependence treatments among Medicaid beneficiaries were common, including measures that were inconsistent with the guideline (i.e., copayments, stepped-care approaches, requirements for enrollment in counseling to obtain medication, limitations on number of treatment courses, and not allowing combined treatments) (2,3). Only New Mexico had medication-coverage policies for the entire Medicaid population consistent with current guideline recommendations to reduce barriers to tobacco-dependence treatment.
The findings in this report are subject to at least two limitations. First, although all but two states provided some supporting documentation, only 37% provided complete documentation of all covered treatments. Lack of confirmatory documentation for any self-reported data increases the likelihood of reporting errors. Second, certain percentages of Medicaid coverage in this report might differ from those in previous survey years because of previous reporting errors, not because coverage levels changed. In most cases, this resulted from particular states reporting data on managedcare organization voluntary coverage of tobacco-dependence treatments and not on Medicaid coverage policies.
Community and policy interventions that increase tobacco-use cessation include increasing the price of tobacco products, sustained media campaigns that encourage cessation and provide information about available treatments, comprehensive smoke-free policies in workplaces and public places, and state-funded tobacco-cessation quitlines (3). Although free, proactive counseling services might be available to Medicaid enrollees through state quitlines, and certain quitlines provide pharmacotherapy to Medicaid enrollees, many state quitlines do not have the capacity to provide comprehensive services (8) . Thus, Medicaid partnerships with the state quitlines and coverage for telephone counseling and medications can help ensure that Medicaid recipients receive the services that will maximize their chances of quitting successfully.
Recently, the Institute of Medicine (IOM) called for eliminating all tobacco use in the United States (4). In addition to recommending regulation of tobacco products and full funding of comprehensive tobacco prevention and control programs at the CDC-recommended level, IOM specifically called for all insurance, managed-care, and employee benefit plans, including Medicaid, to cover reimbursement for effective smoking-cessation programs. Fully covering all recommended tobacco-dependence treatments, eliminating restrictions and barriers to using treatments, promoting treatment use, and educating Medicaid recipients and providers about coverage are all critical to reducing tobacco use.
Investigation of Progressive Inflammatory Neuropathy Among Swine Slaughterhouse WorkersMinnesota, 2007-2008
On January 31, this report was posted as an MMWR Early Release on the MMWR website (http://www.cdc.gov/ mmwr).
On October 29, 2007, the Minnesota Department of Health (MDH) was notified by a tertiary-care provider of unexplained neurologic illnesses among workers in a swine slaughterhouse (plant A) in southeast Minnesota. As a result, MDH initiated a detailed investigation at plant A to characterize the outbreak. This report describes the ongoing investigation and outbreak-control measures undertaken by state public health officials and CDC.
Plant A, located in southeastern Minnesota, employs approximately 1,200 workers and processes 18,000 pigs per day. After being notified of the illnesses, MDH investigators initiated active case finding, interviewed workers at plant A, and reviewed the plant's occupational health and employment records. As of January 28, 2008, a total of 12 workers at plant A had been identified with confirmed (eight workers), probable (two), or possible (two) progressive inflammatory neuropathy (PIN) (Box). Illness onset ranged from November 2006 through November 2007. Median age of the 12 patients was 31 years (range: 21-51 years); six patients were female. All 12 patients reported being healthy before the onset of neurologic symptoms.
Symptoms ranged from acute paralysis to gradually progressive symmetric weakness over periods ranging from 8 to 213 days. Severity ranged from minor weakness and numbness to paralysis predominantly in the lower extremities affecting mobility. Eleven patients had evidence of axonal or demyelinating peripheral neuropathy by electrodiagnostic testing. All 12 patients reported either working at or having regular contact with an area where swine heads were processed (known as the head table), which was located within a larger processing area in plant A known as the warm room. A case-control study was conducted among plant A workers to identify specific risk factors associated with illness. The 10 patients with confirmed or probable cases were included in the study, along with two stratified control groups: 1) a random selection of 48 healthy warm-room workers and 2) all 65 healthy head-table workers. Statistically significant (p<0.05) differences were calculated by chi-square test. Blood samples and throat swabs were collected from all consenting case-patients and controls. As of January 30, laboratory investigations had not identified any infectious agent from the blood and throat-swab specimens that would explain the occurrence of PIN.
Results of the case-control study indicated that casepatients (seven of 10, 70%) were significantly more likely to have worked at the head table than the warm-room controls (12 of 48, 25%) (odds ratio [OR]: 7.0; 95% confidence interval [CI] = 1.3-42.2; p = 0.009). Case-patients also were more likely to have removed brains or remaining skeletal muscle from the pig head (a process known as backing heads) (four of 10, 40%) than controls (two of 46, 4%) (OR: 15.3; CI = 1.8-163.4; p = 0.006). Among headtable workers, case-patients were significantly more likely to have removed brains or skeletal muscle from the head (four of seven, 57%) than head-table controls (eight of 65, 12%) (OR: 9.50; CI = 1.40-70.2; p = 0.01). Illness was not determined to be associated with previous travel outside or within the United States; exposure to chemicals, fertilizers, or insecticides; use of medications; or receipt of previous vaccinations.
An environmental assessment of the plant was conducted on November 28, 2007. Standard personal protective equipment (PPE) used by workers at plant A included hard hats, laboratory coats (including some that were shortsleeved), boots, hearing protection, eye protection, and specialized gloves that varied with the particular task of the worker. A compressed air device was used in the plant to harvest brain tissue from pig heads at the head table. The device was placed into the skull of the pig through the foramen magnum, and the force of the air disrupted the brain material into a liquefied form that made it easier to remove (a technique known as "blowing brains"). This technique caused generation of small droplets and splatter, possibly including aerosolized brain material, to which workers operating the device and others nearby might have been exposed. In response to the investigation, plant A voluntarily suspended harvesting of brains and instituted additional mandatory PPE on November 28, 2007, including face shields and long sleeves, for workers stationed at the head table and other workers who chose to use additional PPE.
Results of Case-Finding Survey
A survey of the 25 federally inspected swine slaughterhouses with >500 employees in the United States indicated that only three plants (plant A in Minnesota and plants in Nebraska and Indiana) reported recent use of compressed air to extract pig brains. To date, no cases of PIN have been identified in association with workers at the Nebraska plant. However, several workers at the Indiana plant have been preliminarily identified with neurologic illnesses and similar histories of exposure to headprocessing activities at that slaughterhouse. Further assessments of these patients, and additional measures to identify other workers with illness, are being conducted in Indiana. As a result of this investigation, all three plants have stopped using compressed air to extract brain material.
Editorial Note: This report summarizes an ongoing investigation of PIN, a syndrome that appears to be associated with swine slaughterhouse workers who process pig heads. Several clinical and laboratory features of this illness and the distinctive epidemiology associated with patients appear unique. Pigs slaughtered at plant A have passed inspection by the U.S. Department of Agriculture Food Safety and Inspection Service, and the investigation has not identified any foodborne risk to the general population.
The investigation in Minnesota indicates that PIN appears associated with having worked at the head table, where a compressed-air device was used to extract pig brains. In the process of blowing compressed air into the pig skull, brain material might have been splattered or even aerosolized, and workers might have been exposed through inhalation or contact with mucous membranes. One hypothesis for development of PIN is that worker exposure to Upon learning of the initial cluster, CDC solicited reports of similar allergic-type reactions among hemodialysis patients nationally through nephrology e-mail lists and public health notifications. In response to these casefinding measures, CDC was contacted on January 9, 2008, by a dialysis supply company that had received reports during the previous 2-week period of approximately 50 similar reactions among adult hemodialysis patients at dialysis facilities in six states. A second supply company reported learning of similar reactions from dialysis facilities as early as December 10, 2007 . CDC alerted the Food and Drug Administration (FDA) to these nationwide reports of allergic-type reactions on January 9, 2008, and has been collaborating with FDA on the investigation.
As part of the investigation, CDC has created a working case definition for these reactions. A confirmed case of acute allergic-type reaction has been defined as an episode of anaphylactic or anaphylactoid reaction characterized by angioedema (particularly swelling of lips/mouth, tongue, throat, or eyelids) or urticaria. A probable case has been defined as an episode that includes at least two of the following signs and symptoms: 1) generalized or localized sensations of warmth; 2) numbness or tingling of the extremities; 3) difficulty swallowing; 4) shortness of breath, audible wheezing, or chest tightness; 5) low blood pressure/ tachycardia; or 6) nausea or vomiting.
Of the episodes reported as of January 30, CDC has identified 65 confirmed or probable cases among 53 hemodialysis patients that occurred during November 19, 2007-January 21, 2008, at 19 dialysis facilities in 12 states. CDC currently is investigating an additional 36 possible cases. Most reactions resolved after interruption of the dialysis session or treatment with diphenhydramine or steroids at the facility. Other than the eight episodes reported by MDHSS, all cases have occurred among adults.
One common factor among the cases being investigated was receipt of heparin (1,000 units/mL) from 30-mL or 10-mL vials manufactured by Baxter. Intravenous heparin is administered during most hemodialysis sessions to prevent clotting of the access and dialysis circuit. In 61 (94%) of the 65 cases, the affected patient received Baxter heparin during hemodialysis. Dialyzers from four different companies were being used when the reactions occurred. The most commonly used dialyzers, manufactured by Fresenius Medi-cal Care (Waltham, Massachusetts), were being used in 26 (40%) of the episodes. Other exposures have not been ruled out as potential causes of the reactions, and CDC is conducting additional epidemiologic studies to examine those exposures.
On January 17, 2008, Baxter announced a voluntary recall of nine lots of heparin, based on reports the company had received (1). All nine lots were produced at a single plant; eight of the nine lots were produced during September-November 2007. Despite the January 17 recall, an additional reaction occurred on January 21, 2008, after a hemodialysis patient was administered Baxter heparin from one of the recalled lots. CDC has found indications of delays in removing the recalled lots of heparin from distribution, which might result in continued exposures. In addition, these reactions might not be limited to hemodialysis settings. One cardiac-care facility has reported seven allergic-type reactions among cardiac patients who received heparin from lots that were later recalled. CDC and state health departments are investigating these reactions.
Reported by: G Turabelidze, MD, Missouri Dept of Health and Senior Svcs; A Elward, MD, Washington Univ School of Medicine; M Jones, BJC Healthcare, St. Louis, Missouri. PR Patel, MD, M Arduino, DrPH, C Gould, MD, N Shehab, PharmD, K Sunkavalli, MPH, Div of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases; S Schillie, MD, D Blossom, MD, A Kallen, MD, J Jaeger, MD, EIS officers, CDC.
Editorial Note: The temporal and geographic distribution of these reactions in a discrete population of patients suggests common exposure to a health-care product with wide distribution in the United States. Previous clusters of acute allergic-type reactions among hemodialysis patients have been attributed to certain types of dialyzer membranes, ethylene oxide (used by the manufacturer as a sterilant), angiotensin-converting enzyme inhibitors, and the reuse of dialyzers (2,3). However, based on preliminary findings, these previously recognized causes of allergic-type reactions in dialysis patients are unlikely to explain this outbreak. Heparin is a biologic product rarely associated with anaphylactic reactions (4).
CDC is conducting additional case-finding activities and epidemiologic studies to define the scope of the outbreak and is exploring options for laboratory testing to further characterize these reactions. Health-care providers should 1) immediately discontinue use of and segregate the recalled lots of heparin, 2) report medication reactions to MedWatch, the online FDA reporting system for adverse medication events,* and 3) report to their state or local health departments any acute allergic-type reactions that have occurred since November 2007 in patients receiving hemodialysis or intravenous medication infusion. Health departments are asked to report reactions to CDC by telephone (404-639-4514 or 404-639-4273) or e-mail (dblossom@cdc.gov or ppatel@cdc.gov).
Notice to Readers

Guidance for Presentation of Economic Studies to the Advisory Committee on Immunization Practices
The charter of the Advisory Committee on Immunization Practices (ACIP) states that committee deliberations on the appropriate use of vaccines should include consideration of population-based studies such as efficacy, costbenefit, and risk-benefit analyses (1) . As the number and cost of vaccines have increased, economic analyses have become an essential aspect of the development of policy recommendations for their use. To ensure that economic data presented to the ACIP and its working groups are of the highest scientific quality, readily understandable, and uniform in presentation, CDC economists have developed Guidance for Health Economics Studies Presented to the ACIP. This guidance, approved by ACIP on June 27, 2007, mandates formal technical review of any economic study before its presentation to the ACIP, effective as of the ACIP meeting, June 25-26, 2008.
The Guidance requires that all economic data presented to the ACIP be reviewed by anonymous peer reviewers within CDC. When a reviewer with a particular area of economic expertise is not available within CDC, external reviewers may be used. Materials to be submitted for review must include a report that provides the methods and results of the study, slides, and other presentation materials as needed. The report and other materials must be sent to the appropriate ACIP working group no later than 8 weeks before the ACIP general meeting or working group meeting at which the analysis is scheduled to be presented. Reviewers will consult with relevant CDC subject-matter 
Notice to Readers
Sixth International Conference on Emerging Infectious Diseases
The sixth International Conference on Emerging Infectious Diseases will be held March 16-19, 2008, at the Hyatt Regency Atlanta Hotel in Atlanta, Georgia. The conference brings together public health professionals to encourage exchange of scientific and public health information on global emerging infectious diseases.
The conference will include plenary and panel sessions and oral and poster presentations. Topics will include antimicrobial resistance, bioterrorism and preparedness, foodborne and waterborne illnesses, global health, molecular diagnostics and epidemiology, nosocomial infections, respiratory and vaccine-preventable diseases, socioeconomic and political factors, vectorborne diseases, and zoonotic diseases. Additional information, including registration instructions and lists of keynote speakers, plenary sessions, and panel sessions, is available at http://www.iceid.org. Since 1989, data on weight gain of women during pregnancy have been collected on U.S. birth certificates. Weight gain of >40 pounds during pregnancy is not recommended for women having a singleton birth, regardless of the woman's height and prepregnancy weight. Excessive weight gain is associated with greater risk for gestational diabetes, preeclampsia, and other adverse conditions during pregnancy and complications of delivery for both mother and infant. From 1990 to 2005, the percentage of women overall who gained >40 pounds increased from 15% to 20%; the percentage who gained >40 pounds also increased among nonHispanic white, non-Hispanic black, and Hispanic women. Non-Hispanic white women were more likely than non-Hispanic black and Hispanic women to gain >40 pounds during pregnancy in 1990, 2000, and 2005. Table II. † † Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV , which appears quarterly. § § Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. One case occurring during the 2007-08 influenza season has been reported. ¶ ¶ No measles cases were reported for the current week. *** Data for meningococcal disease (all serogroups) are available in Table II. † † † No rubella cases were reported for the current week. § § § Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
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Mid. 2  10  21  26  39  6  19  36  63  73  13  7  23  39  34  Delaware  -0 11  12  32  50  65  6  10  22  35  51  4  3  8  16  6  Alaska  -0  1  ---0  2  2  2  -0  0  --California  10  10  29  42  61  3  7  16  26  37  4  2  8  15  6  Hawaii  -0 12  69  213  93  194  5  4  14  19  24  -3  11  -17  Delaware  1  12  34  32  34  -0  1  -1  -0  1  --District of Columbia  -0  7  ---0  1  ---0  0  --Florida  2  1  11  7  3  3  1  7  9  7  -1  7  -7  Georgia  -0  3  1  -1  1  3  4  1  -0  3  -3  Maryland§   9  31  130  48  134  1  1  5  6  6  -0  2  -3  North Carolina  -0 5  17  48  43  76  44  40  156  140  261  2  15  112  8  12  Delaware  -0  2  ---0  0  ---0  2  -2  District of Columbia  -0  1  -1  -0  0  ---0  1  --Florida  3  3  17  9  24  -0  124  8  124  -0  3  --Georgia  -0  3  1  8  31  5  12  42  17  1  0  6  3  3  Maryland†   2  2  6  8  19  -8  18  8 2  21  40  19  113  -3  14  6  4  -0  4  --Arizona  1  3  13  3  32  -2  12  5 -57  77  3  1  8  5  4  6  10  29  31  37  Colorado  -10  24  5  53  -1  17  -6  -2  6  1  8  Idaho§   -3  9  9  12  1  1  16  10 50  112  243  292  352  -9  38  3  6  2  27  70  85  128  Alaska  2  1  5  4  3  N  0  0  N  N  -0  1  -2  California  42  85  153  239  305  -5  33  3  3  2  22  61  75  113  Hawaii  -1  13  19  --0  1  ---0  3  4  -Oregon§   2  6  16  24  29  -1  11  -3  -1  6  6  7  Washington  4  11  90  6  15  -1  18  ---2  20  -6 American Samoa - -0  0  ---0  1  1  -20  40  60  92  221  Alaska  -0  0  ---0  0  ---0  1  -1  California  N  0  0  N  N  -0  0  --7  37  57  61  208  Hawaii  -0  0  ---0  1  1  --0  2 --0  2  --Louisiana  -1  8  1  24  -0  5  ---0  3  --Oklahoma  -0  0  ---0  11  ---0  7  --Texas¶   156  152  475  434  460  -0  18  ---0  10  --Mountain  3  42  130  60  274  -0  36  ---1  143  --Arizona  -0  0  ---0  8  ---0  10  --Colorado  -19  62  9  107  -0  17  ---0 ---------------Guam  -3  24  4  44  -0  0  ---0  0  --Puerto Rico  -11  37  11  38  -0  0  ---0  0  --U.S. Virgin Islands  -0  0  ---0  0  ---0  0  -- 
S. Atlantic
1 - - - 0 2 - 1 - 0 2 - - District of Columbia - 0 5 - 4 - 0 1 - - - 0 1 - -- 0 2 - 1 - 0 3 1 2 - 0 2 - 1 Idaho § 1 0 2 2 - - 0 1 - 1 1 0 1 1 - Montana § - 0 2 - - - 0 1 - - - 0 1 - - Nevada § - 0 2 - 1 - 1 3 - 6 - 0 2 - 2 New Mexico § - 0 1 - - - 0 2 - 2 - 0 1 - 2 Utah - 0 2 - - - 0 2 2 - - 0 3 1 1 Wyoming § - 0 1 - 1 - 0 1 - - - 0 1 - 1 Pacific1 - - - 0 2 1 - - 0 0 - - Oregon § - 1 4 7 3 2 1 4 5 1 0 - 0 2 1 - Washington 1 1 5 1 1 1 1 6 1 2 - 0 2 - - American Samoa - 0 0 - - - 0 13 - - N 0 0 N N C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 1 - 1 - 0 0 - - Puerto Rico - 1 5 - 5 - 1 5 2 7 - 0 1 - 2 U.S. Virgin Islands - 0 0 - - - 0 0 - - - 0 0 - -W.N. Central - 5 483 - 9 - 0 8 - 7 - 1 5 - 8 Iowa - 1 11 - 2 - 0 1 - 1 - 0 3 - 1 Kansas - 0 2 - 1 - 0 1 - - - 0 1 - 1 Minnesota - 1 483 - 6 - 0 8 - 3 - 0 4 - - Missouri - 0 4 - - - 0 1 - 1 - 0 2 - 5 Nebraska § - 0 2 - - - 0 1 - 2 - 0 2 - - North Dakota - 0 2 - - - 0 1 - - - 0 1 - - South Dakota - 0 0 - - - 0 1 - - - 0 1 - 1
8 - - - 0 4 - 2 - 0 4 - - South Carolina § - 0 4 - 1 - 0 1 - - - 0 1 - 2 Virginia § - 1 6 6 2 5 2 2 - 1 6 - 7 - 0 2 - 2 West Virginia - 0 9 - - - 0 1 - - - 0 1 - - E.S. Central - 1 5 - 2 - 1 3 1 5 - 1 3 - 1 0 Alabama § - 0 3 - - - 0 1 1 - - 0 2 - 2 Kentucky - 0 2 - - - 0 1 - 1 - 0 2 - - Mississippi - 0 1 - - - 0 1 - 1 - 0 2 - 4 Tennessee § - 0 4 - 2 - 0 2 - 3 - 0 2 - 4 W.S. Central - 1 6 - 4 1 1 1 2 2 4 - 2 7 - 7 Arkansas § - 0 1 - - - 0 1 - - - 0 2 - - Louisiana - 0 1 - 1 - 0 2 - 2 - 0 3 - 5 Oklahoma - 0 0 - - 1 0 2 1 - - 0 3 - 1 Texas § - 1 6 - 3 - 1 1 2 1 2 - 1 4 - 1 Mountain - 1 3 1 2 - 1 6 1 3 - 1 4 - 6 Arizona - 0 1 - - - 0 3 - - - 0 2 - 2 Colorado - 0 1 1 - - 0 2 1 3 - 0 2 - - Idaho § - 0 2 - - - 0 2 - - - 0 2 - 1 Montana § - 0 2 - 1 - 0 1 - - - 0 1 - - Nevada § - 0 2 - 1 - 0 1 - - - 0 1 - 1 New Mexico § - 0 1 - - - 0 1 - - - 0 1 - 1 Utah - 0 2 - - - 0 3 - - - 0 2 - 1 Wyoming § - 0 1 - - - 0 0 - - - 0 1 - - Pacific 6 2 9 1 8 8 6 3 9 1 1 1 1 - 4 1 2 - 2 0 Alaska - 0 2 - - - 0 1 - 2 - 0 1 - - California 6 2 9 18 8 5 2 8 9 5 - 3 9 - 19 Hawaii N 0 0 N N - 0 0 - - - 0 1 - - Oregon § - 0 1 - - 1 0 2 2 3 - 0 3 - 1 Washington - 0 7 - - - 0 3 - 1 - 0 6 - - American Samoa N 0 0 N N - 0 0 - - - 0 0 - - C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 2 - - - 0 0 - - Puerto Rico N 0 0 N N - 0 1 - 1 - 0 1 - - U.S. Virgin Islands - 0 0 - - - 0 0 - - - 0 0 - -- 0 0 - - - 0 2 - - North Dakota - 0 4 - - 1 0 5 2 - - 0 0 - - South Dakota - 0 7 1 8 - 0 2 - - - 0 1 - -
- 1 1 7 1 - 1 1 3 4 - - 0 1 5 - - Louisiana - 0 2 - 1 - 0 0 - - - 0 1 - - Oklahoma - 0 26 - - - 0 22 - 4 - 0 20 - - Texas † - 1 6 3 3 1 0 1 4 - 0 0 - - - 1 5 - 1
Mountain
4 - 0 1 - - Colorado - 6 14 5 40 - 0 0 - - - 0 2 - - Idaho † 1 0 4 1 7 - 0 0 - - - 0 1 - - Montana † - 1 7 4 5 - 0 3 - - - 0 1 - - Nevada † - 0 6 - 4 - 0 2 - - - 0 0 - - New Mexico † - 1 7 - 5 - 0 2 - - - 0 1 - - Utah - 6 27 6 12 - 0 2 - - - 0 0 - - Wyoming † - 0 2 - 8 - 0 4 1 - - 0 2 - - Pacific 4 14 124 16 46 - 4 10 7 12 - 0 2 - - Alaska 1 0 6 5 8 - 0 6 4 8 N 0 0 N N California - 6 24 - 26 - 3 8 3 4 - 0 2 - - Hawaii - 0 1 - 2 N 0 0 N N N 0 0 N N Oregon † - 1 1 4 5 8 - 0 3 - - - 0 1 - - Washington 3 3 106 6 2 - 0 0 - - N 0 0 N N American Samoa - 0 0 - - N 0 0 N N N 0 0 N N C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 0 - - - 0 0 - - N 0 0 N N Puerto Rico - 0 1 - - - 0 5 1 6 N 0 0 N N U.S. Virgin Islands - 0 0 - - - 0 0 - - - 0 0 -1 - 0 2 - - Montana § - 2 9 3 7 - 0 0 - - - 0 2 - 2 Nevada § - 5 1 2 - 1 8 - 0 3 - 1 - 0 1 0 - 8 New Mexico § - 5 1 3 - 1 9 - 0 3 - 5 - 2 6 - 9 Utah - 4 17 4 10 - 1 9 - 1 - 0 5 - 1 Wyoming § - 1 5 8 9 - 0 0 - - - 0 5 1 1 2
Pacific
0 1 1 - - 0 0 - - - 0 1 1 - C.N.M.I. - - - - - - - - - - - - - - - Guam - 0 5 - - N 0 0 N N - 0 3 1 1 Puerto Rico - 13 55 5 46 - 0 0 - - - 0 2 - 8 U.S. Virgin Islands - 0 0 - - - 0 0 - - - 0 0 - -
